Press release

Oncopeptides publishes the 2023 Annual Report

April 22, 2024 Regulatory

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the 2023 Annual Report has been published.

“2023 was a year when we set ourselves up for success in Europe. We built the foundation in Germany where we now have a full team in place and have secured a price that reflects our scientific innovation. This was a critical achievement to ensure a reference price point for the rest of Europe where we during the year worked intensively to progress market access,” says Sofia Heigis, CEO of Oncopeptides. “Commercializing a new drug doesn’t happen overnight, but I am fully convinced that we are on the right track and that we slowly but surely have started to gain speed.” 

The Annual Report for 2023 is available in PDF format at Oncopeptides’ web site under financial reports.